Navigation Links
Alzheimer's disease drug treats traumatic brain injury, report GUMC researchers
Date:7/12/2009

Vienna, Austria The destructive cellular pathways activated in Alzheimer's disease are also triggered following traumatic brain injury, say researchers from Georgetown University Medical Center (GUMC). They say this finding suggests that novel therapy might successfully target both conditions.

In an oral presentation at the Alzheimer's Association 2009 International Conference on Alzheimer's Disease, the scientists will show that deactivating these pathways in part by using a gamma secretase inhibitor - a class of Alzheimer's disease drugs currently being tested - reduced loss of neurons in animal models of traumatic brain injury and protected the animals against motor and cognitive deficits.

"The goal for both diseases is to prevent neuronal cell death, and this study suggests that one therapy could possibly work for both," says the study's lead author, neuroscientist Mark Burns, PhD, an assistant professor at GUMC.

Both disorders are associated with build-up of beta amyloid, a toxic brain peptide. This substance is commonly found in the brains of elderly patients who died from Alzheimer's disease, but has also been found in a third of traumatic brain injury victims, some of whom are children, Burns says. It is also known that people who experience such a brain injury have a 400 percent increased risk of developing Alzheimer's disease.

Burns says that buildup of beta amyloid occurs in a second wave of damage that follows immediate "necrotic" death of nerve cells after traumatic brain injury. This secondary injury can last months, if not years, resulting in large holes within brain tissue.

Amyloid peptides are produced when a long brain protein known as the amyloid precursor protein (APP) is cut in two by the enzyme beta secretase, and then cut once again by a second enzyme known as gamma secretase. Agents that inhibit the activity of gamma secretase are now being studied as treatment for Alzheimer's disease.

In this study, researchers used mice that were either treated with DAPT, an experimental gamma secretase inhibitor, or mice which were "BACE knock-outs" so called because they were genetically altered in such a way that they could not produce beta secretase. In unaltered and untreated "normal" mice, brain injury resulted in a rapid accumulation of beta amyloid, along with cognitive and motor deficits. But DAPT and BACE knock-out mice had brain lesions that were as much as 70 percent smaller than control animals and they experienced minimal impairment.

The findings further cement the connection between Alzheimer's disease and traumatic brain injury, Burns says, and show that "modulation of beta and gamma secretase may provide novel therapeutic targets for the treatment of traumatic brain injury."


'/>"/>

Contact: Karen Mallet
km463@georgetown.edu
215-514-9751
Georgetown University Medical Center
Source:Eurekalert

Related biology news :

1. Paradigm shift in Alzheimerss research: new treatments
2. Results from trials of DHA in Alzheimers disease and age-related cognitive decline
3. Toward an explanation for Crohns disease?
4. Work in mice will contribute to the study of hereditary diseases that lead to blindness
5. Faster, more cost-effective DNA test for crime scenes, disease diagnosis
6. UTSA infectious disease researchers advancing vaccine against Valley fever
7. Research network wins approximately £5.7 million to target human and animal diseases in Africa
8. U of M study finds new insight on therapy for a devastating parasitic disease
9. NIH expands Human Microbiome Project; funds sequencing centers and disease projects
10. Study shows Chronix technology using serum DNA can identify early presence of disease
11. Targeting helpers of heat shock proteins could help treat cancer, cardiovascular disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2017)... N.Y. , June 23, 2017  IBM (NYSE: ... dairy research, today announced a new collaboration using next-generation ... chances that the global milk supply is impacted by ... Cornell University has become the newest academic institution to ... a food safety initiative that includes IBM Research, Mars, ...
(Date:5/16/2017)... TEANECK, N.J. , May 16, 2017  Veratad ... leading provider of online age and identity verification solutions, ... the K(NO)W Identity Conference 2017, May 15 thru May ... Ronald Regan Building and International Trade Center. ... across the globe and in today,s quickly evolving digital ...
(Date:4/24/2017)... , April 24, 2017 ... and partner with  Identity Strategy Partners, LLP (IdSP) ... "With or without President Trump,s March 6, 2017 ... Terrorist Entry , refugee vetting can be instilled with ... resettlement. (Right now, all refugee applications are suspended ...
Breaking Biology News(10 mins):
(Date:8/23/2017)... ... August 23, 2017 , ... ... ability to manipulate 3D models of pediatric patients’ neuroanatomy and accurately tailor radiation ... of the Journal of Medical Imaging. The advance is reported in an article ...
(Date:8/23/2017)... ... 22, 2017 , ... Patients suffering from gum disease and failing implants now ... Malik. Dr. Malik, of Broward Center for Laser Periodontics and Implants , ... future of dentistry with regenerative periodontal procedures. , "I initially became ...
(Date:8/23/2017)... Virginia (PRWEB) , ... August 23, 2017 , ... NDA ... PhD, former Director of the Office of Device Evaluation at the FDA’s Center for ... industries, has joined the firm as an Expert Consultant. , Prior to his FDA ...
(Date:8/22/2017)... ... August 22, 2017 , ... One ... is the practice of opioid-dose sparing. Opioid-dose sparing refers to the reduction of ... including with non-steroidal anti-inflammatory drugs (NSAIDs). , The potential for new therapies to ...
Breaking Biology Technology: